Biotech News

Sana Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

Sana Biotechnology (SANA)Sana Biotechnology2026-06-25 13:46 ESTEarnings

Shared 12-month clinical results of ongoing UP421 type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression are safe and well-tolerated, evade detection by the immune system, and continue to function one year post-transplant New England

Open original release

Related news

SANASana Biotechnology2026-07-01 13:00 EST

Sana Biotechnology Announces Symposium Presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026

SANASana Biotechnology2026-06-25 13:46 EST

Sana Biotechnology to Present at June 2026 Investor Conferences

SANASana Biotechnology2026-06-25 13:46 EST

Sana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) Facility

SANASana Biotechnology2026-06-25 13:46 EST

Sana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPs

SANASana Biotechnology2026-06-25 13:46 EST

Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates

SANASana Biotechnology2026-06-25 13:46 EST

Sana Biotechnology to Present at December 2025 Investor Conferences

SANASana Biotechnology2026-06-25 13:46 EST

Sana Biotechnology Announces Publication in Nature Biotechnology of in vivo Gene Editing of Human Hematopoietic Stem Cells in Preclinical Models Using the Fusogen Platform

SANASana Biotechnology2026-06-25 13:46 EST

Sana Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference

SANASana Biotechnology2026-06-25 13:46 EST

Sana Biotechnology Appoints Brian Piper as Executive Vice President, Chief Financial Officer

SANASana Biotechnology2026-06-25 13:46 EST

Sana Biotechnology to Present at March 2026 Investor Conferences

View all latest news

Sana Biotechnology

Sana Biotechnology is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

SANAZimmer Biomet2026-07-14 12:13 EST

Zimmer Biomet Names Chintan Desai President of Asia Pacific Region

SANAZimmer Biomet2026-07-13 12:14 EST

Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results

SANABMYBristol-Myers Squibb Company2026-07-13 10:59 EST

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

SANAGSK plc2026-07-13 07:00 EST

Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer

SANAMerck2026-07-10 19:01 EST

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

Stock data

Close: 3.64 USD
Market cap: 1.07B USD
Exchange: NASDAQ
Sector: Biotechnology
Location: United States